Open access publications in the SLU publication database

Abstract

Obesity is a public health concern and requires effective management with multiple approaches. Dietary supplements of bioactive compounds that can improve fatty acid oxidation and thermogenesis are currently in focus to develop anti-obese food ingredients/nutraceuticals without side-effects. Dietary 1,3-diacylglycerol (DAG) and supplementation of α-lipoic acid (LA) have been shown to reduce fat accumulation and improve lipid profile while phytosterols (PS) are known for reducing blood cholesterol.

In this thesis, novel lipid derivatives of LA with PS and 1,3-DAG were synthesized based on the hypothesis, that they would possess advantages over the individual constituents in controlling obesity due to increased stability, solubility, and bioavailability. A mild esterification method was developed to synthesize conjugates of LA and its reduced form (DHLA), with PS and 1,3-DAG yielding 60-80% of the products. The novel DHLA derivatives showed higher in vitro free radical scavenging capacity than the corresponding LA derivatives, and were comparable to pure DHLA.

In a pilot in vitro study, LA derivative with 1,3-dilaurin (diLaLA) was completely hydrolyzed by pancreatic lipase, releasing monolipoate, C12:0 and LA. Free LA was detected in plasma 2 h after oral administration of diLaLA to mice. Effects of diLaLA on body weight and lipid metabolism were evaluated in male C57BL/6J diet-induced obese mice on a high fat diet (HFD) and a control treated only with vehicle. After oral administration of diLaLA at 10, 50 and 250 mg/kg body wt. daily for 6 weeks, body weight was lowered (p<0.05) in high dose group compared with the control and low dose groups. Treatment with high dose also reduced (p<0.05) plasma and hepatic free fatty acid contents, while the concentrations of blood glucose, total cholesterol, and liver triacylglycerol showed a reducing trend compared with the control. Stearoyl-CoA desaturase (SCD)-1 activity, estimated by SCD16 index (C16:1n-7/C16:0), showed lower activity (p<0.05) in white adipose tissues while some key genes involved in fatty acid β-oxidation in liver showed upregulation in the high dose group compared with the control. Oral treatment with diLaLA reduced HFD-induced obesity in mice, possibly through enhanced energy expenditure via β-oxidation and suppressing in vivo lipogenesis, suggesting its potential as a promising candidate against obesity.